Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

  • Technology appraisal guidance
  • TA305
  • Published: 

Review decision – April 2017

Decision to transfer to the static guidance list

The Institute was proposing that the guidance should be transferred to the static guidance list.

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, the guidance will now be transferred to the static guidance list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

Review decision paper

This page was last updated: